DGAP-News: Bancorp Wealth Management New Zealand Limited:

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 11, 2014 at 4:15 AM

DGAP-News: Bancorp Wealth Management New Zealand Limited: Inclusion in Entry Standard from 16 April 2014

DGAP-News: Bancorp Wealth Management New Zealand Limited / Key word(s): Miscellaneous Bancorp Wealth Management New Zealand Limited: Inclusion in Entry Standard from 16 April 2014 11.04.2014 / 10:00 --------------------------------------------------------------------- Inclusion in Entry Standard from 16 April 2014 - Bancorp Group reports record results for 2012/13 financial year - Management maintains continuous dividend policy - Aviation division will be future growth driver Auckland, New Zealand, 11 April 2014: Bancorp Wealth Management New Zealand Limited (Bancorp) will become the first New Zealand company to be listed in the Entry Standard of the Frankfurt Stock Exchange on 16 April 2014. The Bancorp Group has 13 subsidiaries and is active in two divisions, Aviation and Private Banking. The Group's main strategic focus is on the Aviation division, which holds equity investments in the field of insurance brokerage, aviation financing and aviation-related companies. The primary operational focus is on the Group's main growth driver, the current 40% equity investment in Boston Marks Holdings Limited, the world's leading independent specialist for the brokerage of aircraft insurance. The achieved international position shall be expanded continuously by organic and inorganic growth. In its Private Banking division, Bancorp offers an extensive portfolio of banking products, services and investment opportunities in New Zealand. In the 2012/13 financial year, the Bancorp Group generated total operating revenue of NZD 40.7 million or EUR24.4 million (previous year: NZD 13.7 million/EUR8.2 million). This significant revenue growth is primarily attributable to the expansion of the strategic equity investment in Boston Marks Holdings Limited from 20% to 40%, as a result of which the international specialist for the brokerage of aircraft insurance was included in consolidation by the Bancorp Group. Accordingly, around 96% of the revenue generated in the past financial year was attributable to the Aviation division. In light of this situation, Bancorp's management expects the company's positive development to continue. Based on internal planning, the Bancorp Group is currently forecasting a further improvement in profitability in the 2013/14 financial year on the back of constant revenue. The management is also seeking to maintain its continuous dividend policy in order to allow shareholders to participate in the company's profitability on a sustained basis. The dividend for the 2012/13 financial year was NZD 0.045 or EUR0.027, and a dividend of at least the same amount is expected for the current financial year. The listing is being led by Renell Wertpapierhandelsbank AG, Frankfurt/Main. Renell will act as the designated sponsor for the listing, with GFEI Aktiengesellschaft as the listing partner and capital market agency. Board of Directors For further information: www.bancorp.co.nz Exchange rates relate to the respective reporting date. About Bancorp Bancorp Wealth Management New Zealand Limited (ISIN: NZBWME0001S2) and its subsidiaries are a banking group based in New Zealand that provides predominantly Asian clients with banking services and investment opportunities in New Zealand. Within its internationally oriented Aviation division, Bancorp Wealth Management New Zealand Limited holds equity investments in the field of insurance brokerage, aviation financing and aviation-related companies, such as the airport transportation company Auckland Airbus Ltd. Its operating activities are conducted by 13 subsidiaries and equity investments. The shares of Bancorp Wealth Management New Zealand Limited are listed in the Entry Standard of the Frankfurt Stock Exchange. End of Corporate News --------------------------------------------------------------------- 11.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 262811 11.04.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Stavian Group Eyes AI-Driven Southeast Asia Growth

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...